Loading
A phase 1/2 trial of DFP-10917 run by Delta-Fly Pharma, Inc., completed.
Phase I/II Study of DFP-10917 in Patients With Acute Leukemia is a phase 1/2 interventional study registered as NCT01702155 by Delta-Fly Pharma, Inc., with 69 participants enrolled, started 2012-10-10. Conditions recorded: Acute Myeloid Leukemia and Acute Lymphocytic Leukemia. Interventions recorded: DFP-10917.
Shares DFP-10917, Delta-Fly Pharma, Acute myeloid leukaemia and the tag pipeline.
Shares DFP-10917, Delta-Fly Pharma, Acute myeloid leukaemia and the tag pipeline.
Shares Delta-Fly Pharma and the tag pipeline.
Shares Delta-Fly Pharma and the tag pipeline.
Shares Delta-Fly Pharma and the tag pipeline.
Shares Delta-Fly Pharma and the tag pipeline.
Shares Delta-Fly Pharma and the tag pipeline.
Shares Leukaemia (all types), Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/